MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2021
November 13, 2020 at 01:00 am
Share
MEDINET Co., Ltd. provided earnings guidance for the year ending September 30, 2021. For the year ending, the company expects net sales of JPY 810 million, operating loss of JPY 1,775 million, ordinary loss was JPY 1,762 million, loss of JPY 1,768 million and basic loss per share of JPY 11.00.
MEDINET Co., Ltd. is a Japan-based company mainly engaged in cell processing industry and cellular medical products business. It operates through two business segments. The Cell Processing Industry segment mainly engages in comprehensive support services for immune cell therapy, related services including clinical use from companies, universities, research institutes, outsourcing of cell processing for clinical trials and operation of cell culture processing facilities. The Cellular Medical Products segment is mainly engaged in research and development for obtaining approval for manufacture and marketing of cellular medical products. It also provides comprehensive support services for immune cell therapy.
MEDINET CO., LTD. 